Mechanisms of Multidrug Resistance in Cancer Chemotherapy.
Bukowski K, Kciuk M, Kontek R. · 2020
Read Mechanisms of Multidrug Resistance in Cancer Chemotherapy. by Bukowski K, Kciuk M, Kontek R. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7247559.txt.
Introduction
Bukowski and co-authors review why cancer cells stop responding to chemotherapy drugs. Their review appeared in the International Journal of Molecular Sciences. Multidrug resistance is blamed for over 90% of deaths in patients given standard or targeted drugs. Cancer remains one of the main causes of death worldwide, and chemotherapy is still its main treatment.
Cancer cells resist in several ways. They pump drugs out, break them down faster, repair DNA damage more quickly, and change their genes or gene control. The authors sort the main drug classes and explain how each one fails. They also describe new antitumor drugs built to dodge or reverse these defenses, and argue that knowing the resistance routes should guide the search for better treatment plans.
Catalog record
| CREATOR | Bukowski K, Kciuk M, Kontek R. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 83 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mechanisms of Multidrug Resistance in Cancer Chemotherapy By Karol Bukowski, Mateusz Kciuk, Renata Kontek Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms21093233 ABSTRACT Abstract Cancer is one of the main causes of death worldwide. Despite the significant development of methods of cancer healing during the past decades, chemotherapy still remains the main method for cancer treatment. Depending on the mechanism of action, commonly used chemotherapeutic agents can be divided into several classes (antimetabolites, alkylating agents, mitotic spindle inhibitors, topoisomerase inhibitors, and others). Multidrug resistance (MDR) is responsible for over 90% of deaths in cancer patients receiving traditional chemotherapeutics or novel targeted drugs. The mechanisms of MDR include elevated metabolism of xenobiotics, enhanced efflux of drugs, growth factors, increased DNA repair capacity, and genetic factors (gene mutations, amplifications, and epigenetic alterations). Rapidly increasing numbers of biomedical studies are focused on designing chemotherapeutics that are able to evade or reverse MDR. The aim of this review is not only to demonstrate the latest data on the mechanisms of cellular resistance to anticancer agents currently used in clinical treatment but also to present the mechanisms of action of novel potential antitumor drugs which have been designed to overcome these resistance mechanisms. Better understanding of the mechanisms of MDR and targets of novel chemotherapy agents should provide guidance for future research concerning new effective strategies in cancer treatment. Keywords: cancer, multidrug resistance, chemotherapeutics, inhibitors, P-glycoprotein, drug metabolism, growth factors, DNA repair, epigenetic alterations, microRNA 1. INTRODUCTION Cancer is responsible for about 1 in 6 deaths worldwide. It is the second leading cause of death globally, with 8.7 million deaths in 2015 [1]. Factors that are associated with elevated risk of cancer are tobacco use (22% of cancer deaths), lack of physical activity, alcohol use, low vegetable and fruit intake, and high body mass index. These factors are thought to be responsible for approximately one third of cancer deaths. Breast, cervical, lung, thyroid, and colorectal cancers are the most common types of cancer in women, while prostate, lung, colorectal, liver, and stomach cancer are the most common among men [2]. Despite the fact that there are several different methods of cancer treatments, including radiation therapy, surgery, immunotherapy, endocrine therapy, and gene therapy, chemotherapy still remains the most common method of cancer healing. In this paper, we have presented the latest data on the mechanisms of cellular resistance to chemotherapy and chemotherapeutics currently used in clinical treatment as well as on the mechanisms of action of novel potential anticancer agents which have been designed to overcome these resistance mechanisms. 2. TYPES OF CHEMOTHERAPEUTICS Chemotherapeutics can be divided into two classes depending on/regarding their origin. They can either be plant-derived (extracted from plants) [3,4] or of synthetic origin [5,6]. Depending on the mechanism of action, they can be divided into alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic spindle inhibitors, and others (Figure 1) [7,8,9]. [Figure: Classification of commonly used chemotherapeutics depending on their mechanism of action [7,8,9].] Alkylating agents include the oxazsaphosphorines (cyclophosphamide and ifosfamide); nitrogen mustards (busulfan, chlorambucil, and melphalan); hydrazine (temozolomide); platinum-based agents (cisplatin, carboplatin, and oxaliplatin) [7]; and novel, still under investigation OFF-ON-type alkylating agents such as vinyl-quinazolinone (VQ) [10]. Chemotherapeutics belonging to this class of molecules create either inter or intra-strand cross links or transfer alkyl groups to the guanine residues of DNA, which results in mispair formation in DNA bases and prevents strand separation during DNA synthesis [7,8]. Antimetabolites can be divided into several groups: pyrimidine antagonists (cytarabine, 5-fluorouracil (5-FU), gemcitabine, and capecitabine), purine antagonists (fludarabine), purine analogs (6-mercaptopurine, azathioprine, and cladribine), antifolates (methotrexate, pemetrexed, and pralatrexate), and ribonucleotide reductase inhibitors (hydroxyurea). These anticancer drugs interfere with essential biosynthetic pathways, disturb the DNA/RNA synthesis, or cause the formation of DNA strand breaks through inhibition of particular enzymes (dihydrofolate reductase, ribonucleotide reductase, and DNA polymerase) or incorporation of false structural analogues of pyrimidine/purine into DNA [5,7,8]. Topoisomerase I inhibitors (irinotecan and topotecan) and topoisomerase II inhibitors (etoposide; teniposide; and anthracyclines, e.g., idarubicin, daunorubicin, and doxorubicin (DOX)) inhibit topoisomerases activities involved in replication of DNA and cause DNA strand breaks [7,8,11,12]. Mitotic spindle inhibitors such as taxanes (docetaxel and paclitaxel) and vinca alkaloids (vincristine (VCR) and vinblastine) modify the function/formation of spindle microtubules by inhibition of nuclear division (mitotic arrest in metaphase), leading to cell death [7,8]. Recently, Peng et al. [6] demonstrated that one of the newly synthesized N-carbonyl acridines inhibited tubulin polymerization, presenting high antiproliferative activity against human mammary gland/breast cancer cells MB-468 (half-maximum inhibitory concentration—IC50—value comparable to colchicine and paclitaxel). Other chemotherapeutic agents, including some enzymes (l-asparaginase), proteasome inhibitors (bortezomib), tyrosine kinase inhibitors (imatinib and erlotinib), and antibiotics (bleomycin, actinomycin D, and anthracyclines), are characterized by non-homogenous mechanisms of action. While l-asparaginase cleaves the amino acid l-asparagine essential for normal cell metabolism, bortezomib drives the cell to apoptotic death by inhibition of apoptotic protein degradation. Imatinib and erlotinib inhibit tyrosine kinases activities involved in multiple intracellular pathways associated with receptor-mediated growth signaling, leading to cellular dysfunction and subsequent cell death. Bleomycin, an antibiotic, induces formation of free radicals that cause DNA damage and the cell cycle arrest in G2 phase. Another anticancer agent, actinomycin D, intercalates into DNA and interferes in DNA transcription. Anthracyclines exhibit anti-proliferatory effects in the abovementioned processes and inhibit topoisomerase II activity [7]. 3. THE PROBLEM OF DRUG RESISTANCE IN CANCER CHEMOTHERAPY Statistical data shows that over 90% mortality of cancer patients is attributed to drug resistance. MDR of cancer cells during chemotherapy can be associated with a variety of mechanisms, including enhanced efflux of drugs, genetic factors (gene mutations, amplifications, and epigenetic alterations), growth factors, increased DNA repair capacity, and elevated metabolism of xenobiotics (Figure 2). Each of these mechanisms leads to reduction of the therapeutic efficacy of administered drugs, causing more difficulty in tumor treatment [9,13,14,15,16]. [Figure: Mechanisms of chemotherapeutic drug resistance in cancer cells [9,13,14,15,16].] 3.1. Enhanced Efflux of Drugs ATP-binding cassette (ABC) proteins such as P-glycoprotein (P-gp)/ATP-binding cassette subfamily B member 1 (ABCB1) or Breast Cancer Resistance Protein (BCRP) present in the cell membrane are responsible for regulation of distribution, absorption, and excretion of a variety of chemical compounds. Because these proteins protect cells from death caused by high intracellular drug concentration, they can also interfere with drug administration, decreasing its bioavailability, intracellular concentration, and its transition of the blood–brain barrier (BBB). P-gp, highly expressed on the endothelial cell surface contributes to reduced chemotherapeutic drug penetration to the specific sites, especially in case of brain tumor treatment where anticancer agents are generally incapable of passing through the BBB. The size of the tumor also plays a crucial role in drug penetration. Because of the poor blood supply in large tumors, chemotherapeutic agents are usually less efficient in large tumors due to the poor blood supply compared to smaller ones with nearly unlimited access of oxygen and nutrient supply. The P-gp protects the brain from potentially damaging compounds but, at the same time, restricts access of therapeutic agents responsible for higher complexity of the therapy. In most cases, the only way to overcome the barrier is to increase the concentration of the drug, which often leads to systemic toxicity. This is the reason why elevated efflux of the drug has been considered to be